Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

Diana M. Antoniucci, Deborah E. Sellmeyer, John P. Bilezikian, Lisa Palermo, Kristine E. Ensrud, Susan L. Greenspan, Dennis M. Black

Research output: Contribution to journalArticle

Abstract

Context: The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated. Objective: The objective was to examine changes in serum and urinary calcium associated with PTH(1-84) therapy in the PaTH trial and the extent to which a defined algorithm resolved the elevated values. Design, Setting, Participants, and Intervention: A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study. Main Outcome Measure(s): The main outcome measures were fasting serum calcium at baseline and 1, 3, and 12 months and 24-h urinary calcium at baseline and 3 months. Results: In 14% of participants, serum calcium more than 10.5 mg/dl (>2.6 mmol/liter) developed. Following the defined algorithm, 58% of elevated measurements were normal on repeat testing; 38% required discontinuation of calcium and vitamin D supplementation, and one necessitated a decrease in PTH injection frequency to normalize serum calcium. One participant developed transient hypercalcemia between study visits and required hospitalization; the episode resolved with iv hydration and PTH discontinuation. Baseline characteristics associated with the development of hypercalcemia were serum calcium [relative hazards = 1.9 per 0.5 mg/dl (0.12 mmol/liter); 95% confidence interval = 1.1-3.2] and serum 1,25-dihydroxyvitamin D [relative hazard = 1.9 per 10 pg/ml (26 pmol/liter); 95% confidence interval = 1.2-3.1]. Fifteen women (8%) developed hypercalciuria [urinary calcium > 400 mg (100 mmol)/24 h or calcium/creatinine ratio > 0.4]; 80% of cases resolved after discontinuing calcium and vitamin D, 13% without intervention, and one after PTH injection frequency was decreased. Higher baseline urinary calcium excretion was associated with development of hypercalciuria [relative hazard = 1.5 per 50 mg/d (12.5 mmol/d); 95% confidence interval = 1.2-4.0]. Proportions of patients with elevated serum and urinary calcium were similar on single and combination therapy. Conclusions: The frequency of episodic hypercalcemia or hypercalciuria in the PaTH trial was 21%. Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.

Original languageEnglish (US)
Pages (from-to)942-947
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number3
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Alendronate
Parathyroid Hormone
Osteoporosis
Calcium
Serum
Hypercalciuria
Hypercalcemia
Vitamin D
Hazards
Confidence Intervals
Outcome Assessment (Health Care)
Injections

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Antoniucci, D. M., Sellmeyer, D. E., Bilezikian, J. P., Palermo, L., Ensrud, K. E., Greenspan, S. L., & Black, D. M. (2007). Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. Journal of Clinical Endocrinology and Metabolism, 92(3), 942-947. https://doi.org/10.1210/jc.2006-1788

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. / Antoniucci, Diana M.; Sellmeyer, Deborah E.; Bilezikian, John P.; Palermo, Lisa; Ensrud, Kristine E.; Greenspan, Susan L.; Black, Dennis M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 3, 2007, p. 942-947.

Research output: Contribution to journalArticle

Antoniucci, DM, Sellmeyer, DE, Bilezikian, JP, Palermo, L, Ensrud, KE, Greenspan, SL & Black, DM 2007, 'Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis', Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 942-947. https://doi.org/10.1210/jc.2006-1788
Antoniucci, Diana M. ; Sellmeyer, Deborah E. ; Bilezikian, John P. ; Palermo, Lisa ; Ensrud, Kristine E. ; Greenspan, Susan L. ; Black, Dennis M. / Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 3. pp. 942-947.
@article{3460ec6767c34414b2e0c275f4d546f2,
title = "Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis",
abstract = "Context: The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated. Objective: The objective was to examine changes in serum and urinary calcium associated with PTH(1-84) therapy in the PaTH trial and the extent to which a defined algorithm resolved the elevated values. Design, Setting, Participants, and Intervention: A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study. Main Outcome Measure(s): The main outcome measures were fasting serum calcium at baseline and 1, 3, and 12 months and 24-h urinary calcium at baseline and 3 months. Results: In 14{\%} of participants, serum calcium more than 10.5 mg/dl (>2.6 mmol/liter) developed. Following the defined algorithm, 58{\%} of elevated measurements were normal on repeat testing; 38{\%} required discontinuation of calcium and vitamin D supplementation, and one necessitated a decrease in PTH injection frequency to normalize serum calcium. One participant developed transient hypercalcemia between study visits and required hospitalization; the episode resolved with iv hydration and PTH discontinuation. Baseline characteristics associated with the development of hypercalcemia were serum calcium [relative hazards = 1.9 per 0.5 mg/dl (0.12 mmol/liter); 95{\%} confidence interval = 1.1-3.2] and serum 1,25-dihydroxyvitamin D [relative hazard = 1.9 per 10 pg/ml (26 pmol/liter); 95{\%} confidence interval = 1.2-3.1]. Fifteen women (8{\%}) developed hypercalciuria [urinary calcium > 400 mg (100 mmol)/24 h or calcium/creatinine ratio > 0.4]; 80{\%} of cases resolved after discontinuing calcium and vitamin D, 13{\%} without intervention, and one after PTH injection frequency was decreased. Higher baseline urinary calcium excretion was associated with development of hypercalciuria [relative hazard = 1.5 per 50 mg/d (12.5 mmol/d); 95{\%} confidence interval = 1.2-4.0]. Proportions of patients with elevated serum and urinary calcium were similar on single and combination therapy. Conclusions: The frequency of episodic hypercalcemia or hypercalciuria in the PaTH trial was 21{\%}. Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.",
author = "Antoniucci, {Diana M.} and Sellmeyer, {Deborah E.} and Bilezikian, {John P.} and Lisa Palermo and Ensrud, {Kristine E.} and Greenspan, {Susan L.} and Black, {Dennis M.}",
year = "2007",
doi = "10.1210/jc.2006-1788",
language = "English (US)",
volume = "92",
pages = "942--947",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

AU - Antoniucci, Diana M.

AU - Sellmeyer, Deborah E.

AU - Bilezikian, John P.

AU - Palermo, Lisa

AU - Ensrud, Kristine E.

AU - Greenspan, Susan L.

AU - Black, Dennis M.

PY - 2007

Y1 - 2007

N2 - Context: The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated. Objective: The objective was to examine changes in serum and urinary calcium associated with PTH(1-84) therapy in the PaTH trial and the extent to which a defined algorithm resolved the elevated values. Design, Setting, Participants, and Intervention: A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study. Main Outcome Measure(s): The main outcome measures were fasting serum calcium at baseline and 1, 3, and 12 months and 24-h urinary calcium at baseline and 3 months. Results: In 14% of participants, serum calcium more than 10.5 mg/dl (>2.6 mmol/liter) developed. Following the defined algorithm, 58% of elevated measurements were normal on repeat testing; 38% required discontinuation of calcium and vitamin D supplementation, and one necessitated a decrease in PTH injection frequency to normalize serum calcium. One participant developed transient hypercalcemia between study visits and required hospitalization; the episode resolved with iv hydration and PTH discontinuation. Baseline characteristics associated with the development of hypercalcemia were serum calcium [relative hazards = 1.9 per 0.5 mg/dl (0.12 mmol/liter); 95% confidence interval = 1.1-3.2] and serum 1,25-dihydroxyvitamin D [relative hazard = 1.9 per 10 pg/ml (26 pmol/liter); 95% confidence interval = 1.2-3.1]. Fifteen women (8%) developed hypercalciuria [urinary calcium > 400 mg (100 mmol)/24 h or calcium/creatinine ratio > 0.4]; 80% of cases resolved after discontinuing calcium and vitamin D, 13% without intervention, and one after PTH injection frequency was decreased. Higher baseline urinary calcium excretion was associated with development of hypercalciuria [relative hazard = 1.5 per 50 mg/d (12.5 mmol/d); 95% confidence interval = 1.2-4.0]. Proportions of patients with elevated serum and urinary calcium were similar on single and combination therapy. Conclusions: The frequency of episodic hypercalcemia or hypercalciuria in the PaTH trial was 21%. Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.

AB - Context: The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated. Objective: The objective was to examine changes in serum and urinary calcium associated with PTH(1-84) therapy in the PaTH trial and the extent to which a defined algorithm resolved the elevated values. Design, Setting, Participants, and Intervention: A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study. Main Outcome Measure(s): The main outcome measures were fasting serum calcium at baseline and 1, 3, and 12 months and 24-h urinary calcium at baseline and 3 months. Results: In 14% of participants, serum calcium more than 10.5 mg/dl (>2.6 mmol/liter) developed. Following the defined algorithm, 58% of elevated measurements were normal on repeat testing; 38% required discontinuation of calcium and vitamin D supplementation, and one necessitated a decrease in PTH injection frequency to normalize serum calcium. One participant developed transient hypercalcemia between study visits and required hospitalization; the episode resolved with iv hydration and PTH discontinuation. Baseline characteristics associated with the development of hypercalcemia were serum calcium [relative hazards = 1.9 per 0.5 mg/dl (0.12 mmol/liter); 95% confidence interval = 1.1-3.2] and serum 1,25-dihydroxyvitamin D [relative hazard = 1.9 per 10 pg/ml (26 pmol/liter); 95% confidence interval = 1.2-3.1]. Fifteen women (8%) developed hypercalciuria [urinary calcium > 400 mg (100 mmol)/24 h or calcium/creatinine ratio > 0.4]; 80% of cases resolved after discontinuing calcium and vitamin D, 13% without intervention, and one after PTH injection frequency was decreased. Higher baseline urinary calcium excretion was associated with development of hypercalciuria [relative hazard = 1.5 per 50 mg/d (12.5 mmol/d); 95% confidence interval = 1.2-4.0]. Proportions of patients with elevated serum and urinary calcium were similar on single and combination therapy. Conclusions: The frequency of episodic hypercalcemia or hypercalciuria in the PaTH trial was 21%. Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.

UR - http://www.scopus.com/inward/record.url?scp=33947546818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947546818&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-1788

DO - 10.1210/jc.2006-1788

M3 - Article

VL - 92

SP - 942

EP - 947

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -